scholarly journals Rhamnolipids from non-pathogenic Acinetobacter calcoaceticus: Bioreactor-scale production, characterization and wound healing potency

2021 ◽  
Author(s):  
Peili Zhu ◽  
Shiqing Zhang ◽  
Rajat Kumar ◽  
Zhu Zhang ◽  
Zhang Zhang ◽  
...  
2021 ◽  
Vol 10 (1) ◽  
pp. 653-670
Author(s):  
Ahmad Yasser Hamdi Nor Azlan ◽  
Haliza Katas ◽  
Mohd Fauzi Mh Busra ◽  
Nur Atiqah Mohamad Salleh ◽  
Ali Smandri

Abstract Metal nanoparticles have been widely used in the treatment of diabetic wounds owing to their proven antibacterial activity and enhanced wound healing effects. Therefore, in this review, we discuss the use of metal nanoparticles in managing diabetic wounds, mainly silver nanoparticles (AgNPs), gold nanoparticles (AuNPs), and zinc nanoparticles (ZnO nanoparticles), as well as their combination with biomaterials such as chitosan, bacterial cellulose, growth factors, etc. The combination of metal nanoparticles and biomaterials reportedly halts the growth and multiplication of bacterial strains commonly involved in diabetic wounds, including gram-positive (Staphylococcus aureus and Acinetobacter calcoaceticus) and gram-negative bacteria (Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae). Furthermore, these combinations have demonstrated enhanced wound healing of diabetic wounds during in vitro and in vivo studies. Additionally, we highlighted the barriers and challenges associated with the use of metal nanoparticles, including toxicities. Moreover, toxicities were mainly related to the method of synthesis employed, as well as the physical characteristics of nanoparticles, including size, shape, surface charge, and morphology. Collectively, dual-therapy composed of metal nanoparticles and biomaterials has been shown to promote wound healing and can be developed as a promising future therapy for better outcomes in diabetic wound healing.


Author(s):  
Rick L. Vaughn ◽  
Shailendra K. Saxena ◽  
John G. Sharp

We have developed an intestinal wound model that includes surgical construction of an ileo-cecal patch to study the complex process of intestinal wound healing. This allows approximation of ileal mucosa to the cecal serosa and facilitates regeneration of ileal mucosa onto the serosal surface of the cecum. The regeneration of ileal mucosa can then be evaluated at different times. The wound model also allows us to determine the rate of intestinal regeneration for a known size of intestinal wound and can be compared in different situations (e.g. with and without EGF and Peyer’s patches).At the light microscopic level it appeared that epithelial cells involved in regeneration of ileal mucosa originated from the enlarged crypts adjacent to the intestinal wound and migrated in an orderly fashion onto the serosal surface of the cecum. The migrating epithelial cells later formed crypts and villi by the process of invagination and evagination respectively. There were also signs of proliferation of smooth muscles underneath the migratory epithelial cells.


2020 ◽  
Vol 134 (16) ◽  
pp. 2189-2201
Author(s):  
Jessica P.E. Davis ◽  
Stephen H. Caldwell

Abstract Fibrosis results from a disordered wound healing response within the liver with activated hepatic stellate cells laying down dense, collagen-rich extracellular matrix that eventually restricts liver hepatic synthetic function and causes increased sinusoidal resistance. The end result of progressive fibrosis, cirrhosis, is associated with significant morbidity and mortality as well as tremendous economic burden. Fibrosis can be conceptualized as an aberrant wound healing response analogous to a chronic ankle sprain that is driven by chronic liver injury commonly over decades. Two unique aspects of hepatic fibrosis – the chronic nature of insult required and the liver’s unique ability to regenerate – give an opportunity for pharmacologic intervention to stop or slow the pace of fibrosis in patients early in the course of their liver disease. Two potential biologic mechanisms link together hemostasis and fibrosis: focal parenchymal extinction and direct stellate cell activation by thrombin and Factor Xa. Available translational research further supports the role of thrombosis in fibrosis. In this review, we will summarize what is known about the convergence of hemostatic changes and hepatic fibrosis in chronic liver disease and present current preclinical and clinical data exploring the relationship between the two. We will also present clinical trial data that underscores the potential use of anticoagulant therapy as an antifibrotic factor in liver disease.


Sign in / Sign up

Export Citation Format

Share Document